Dr. Bastien in Catalyst Kinetics Group
100-7865 Edmonds Street V3N 1B9 Burnaby, BC, Canada

This new phase 3 clinical trial on high dose B12 for early treatment of ALS is quite impressive. The key with the therapy is starting early in the disease to prevent the oxidative damage from causing too much destruction early on. http://www.neurology.org/cont//14_Supplement/P7.060.short

An interesting article on what appears to be a clear increased risk link between MMR and autism, but only within the African American male population. The analysis of the CDC data indicate that later vaccination would mitigate this increased risk. http://www.translationalneurodegeneration.com/content/3/1/16

Well isn't this interesting

Seems like calcium-channel blockers should not be the choice for women anymore, especially when the cheaper ACE-inhibitors are shown to have a protective effect.